Efficacy and Tolerability of a Hepatoprotective Nutraceutical Formulation in Dogs with Iatrogenic Hepatocellular Injury: A Retrospective Observational Study

Authors

  • Bruna de Felice Department of Environmental , Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, Italy
  • Gianluca Barbato Barbato Clinic Pathology and Clinic for Companion Animals, Via Milano snc, Pachino (SR), Italy
  • Elisa De Paoli Self-employed Veterinarian, Italy
  • Barbara D'Orta Self-employed Veterinarian, Italy
  • Youssef Khalidy Self-employed Veterinarian, Italy
  • Francesco Pascali Self-employed Veterinarian, Italy
  • Barbara Pantalone Self-employed Veterinarian, Italy
  • Paolo Rosi Self-employed Veterinarian, Italy
  • Greta Trussardi Self-employed Veterinarian, Italy
  • Alessandra Zucca Self-employed Veterinarian, Italy
  • Andrea Del Buono DDClinic EPS Research, Caserta, Italy

DOI:

https://doi.org/10.14738/bjhr.1304.11954

Abstract

Objective: To evaluate longitudinal changes in hepatocellular enzyme activity in dogs nutritionally supplemented with a complementary feed 1 based on carrot ( Daucus carota L. ) extract rich in superoxide dismutase (SOD) from phytocomplexes, to modulate hypertransaminasemia induced by therapies for canine leishmaniasis. Methods: Retrospective observational study of 30 client-owned dogs with alanine aminotransferase (ALT) and aspartate transaminase (AST) activity 4 times the reference limit at T0 and reevaluated every month. The endpoints: ALT, AST were assessed at T0, T3, T6, and T12 months. Statistical analysis: ANOVA for repeated measures with Bonferroni correction and Effect Size ( Cohen's D ). Results: ALT activity decreased significantly at T12 - P < .001 . Ninety percent of dogs achieved biochemical normalization within 12 months. Tolerability was 96%. Conclusions: Supplementation showed a clinically relevant reduction in cytolysis markers . The robustness of the effect ( Cohen's d = 2.8 ) supports the efficacy of the formulation in the support of iatrogenic liver injury. Observation and Limitations: Retrospective design • No untreated control group • Limited biomarker panel • No histopathological confirmation • Moderate sample size. Retrospective analysis of medical records; no experimental interventions were performed.

Downloads

Published

2026-07-05

How to Cite

Felice, B., Barbato, G., Paoli, E., D’Orta, B., Khalidy, Y., Pascali, F., … Buono, A. D. (2026). Efficacy and Tolerability of a Hepatoprotective Nutraceutical Formulation in Dogs with Iatrogenic Hepatocellular Injury: A Retrospective Observational Study. British Journal of Healthcare and Medical Research, 13(04), 17–20. https://doi.org/10.14738/bjhr.1304.11954